PRL and pituitary tumor: An ESE survey of 171 patients with aggressive pituitary tumors and carcinomas identified six patients, five with ACTH-secreting and one with a silent prolactin-staining adenoma, who were treated with either dual or single agent ICIs for 2 to 14 months as second-line therapy.